Q3 2021 BUSINESS UPDATE

NOV 9, 2021

COPYRIGHT © ABCELLERA

DISCLAIMER

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

COPYRIGHT © ABCELLERA



STRONG GROWTH OF CORE BUSINESS

17

NEW programs under contract

9

NEW programs started

1

MOLECULE entered clinical testing

155

cumulative programs under contract

$754M

in cash, cash equivalents & marketable securities

$44M

in accounts & accrued receivable

Q3 2021.

BUSINESS UPDATE SUMMARY.

100+ DISCOVERY PROGRAMS ANNUALLY

DOZENS OF IND FILINGS IN HALF THE TIME

OUR VISION.

AbCellera Development → **Partner Development**

Antibody Discovery

Tech Stack



Preclinical

Expansion into GMP / CMC Manufacturing



Phase 1, 2, 3, Approval

155 PROGRAMS UNDER CONTRACT

131 WITH DOWNSTREAM PARTICIPATION

DEAL STRUCTURES

- royalties & milestones
- equity / equity-like
- option to Invest

INDICATIONS INCLUDE

- oncology
- neurodegeneration
- pain
- allergic inflammation
- ophthalmology
- infectious disease
- autoimmune diseases
- women's health
- cardiovascular

COPYRIGHT © ABCELLERA

UNLOCKING INNOVATION

FOR DRUG DEVELOPERS OF ALL SIZES

Next-Gen Modalities


IgGs, IgMs, IgAs


bispecific antibodies


single domain


radioisotope conjugates


CAR-T Cell therapies


CNS-delivered antibodies

moderna · Lilly · GILEAD

REGENERON · gsk · EVEREST MEDICINES

EQRx · NOVARTIS · SANOFI

Pfizer · igm biosciences · KODIAK

BILL & MELINDA GATES foundation · DARPA · DENALI

Ablynx A SANOFI COMPANY · EMPIRICO · angios

Invetx · Autolus · Lyell

MERCK · TACHYON · teva

COPYRIGHT © ABCELLERA

2 NEW PARTNERSHIPS THAT OPEN NEW MARKETS & PIONEER NEW MODALITIES

EVEREST MEDICINES

10 **targets**
multi-year

oncology +
multiple indications

moderna

6 **targets**
multi-year

multiple
indications

COPYRIGHT © ABCELLERA

EXPAND CAPABILITIES AGAINST DIFFICULT-TO-DRUG TARGETS WITH ACQUISITION OF TETRAGENETICS

GPCR and ion channel proteins are high value, difficult-to-drug targets.

Integrating TetraGenetics into our tech stack provides an optimized source of proteins for our antibody discovery efforts and solves a key challenge in pursuing these highly sought-after, but difficult-to-drug targets.



COPYRIGHT © ABCELLERA

CREATING VALUE WITH BISPECIFICS

OrthoMab™ bispecific engineering platform, coupled with our discovery engine, provides partners with a rapid and complete solution for generating tailored, stable, and developable bispecific antibodies.



COPYRIGHT © ABCELLERA

EMPOWER NEXT-GEN ANTI-CD3 ANTIBODIES FOR ONCOLOGY

Large and growing market opportunity in the use of bispecifics specifically for T cell redirection in oncology through CD3 receptor engagement on T cells.



COPYRIGHT © ABCELLERA

CONGRATULATIONS TO INVETX FOR ADVANCING IVX-01 INTO CLINICAL TESTING

IVX-01 is an antibody treatment for an undisclosed chronic indication in dogs.

COPYRIGHT © ABCELLERA

EXPAND CAPABILITIES.
BUILD CAPACITY.
EXTEND COMMERCIAL REACH.

1 **Increase programs** under contract

2 **Forward integration** of our tech stack

3 **Scale** teams and facilities

4 **Further technology** differentiation

5 **Improve speed**, increase **predictive power**

COPYRIGHT © ABCELLERA

Q3 2021

FINANCIALS UPDATE

COPYRIGHT © ABCELLERA

Partnership business on track for strongest year on all key metrics.

of
Discovery Partners



Cumulative # of
Programs Under Contract



Cumulative # of
Program Starts



– **WITHOUT** downstream participation
+ **WITH** downstream participation

Note: Showing year-end figures except for most recent quarter.
Historical results are not necessarily indicative of future results.

COPYRIGHT © ABCELLERA

Five molecules in the clinic, over a dozen in preclinical development.

MOLECULE	STAGE	PARTNER	THERAPEUTIC AREA	PROGRAM TYPE
bamlanivimab (LY-CoV555)	Marketed, Emergency Use Authorization (EUA)	Lilly	• COVID-19	AbCellera Discovery Partnership
bebetelovimab (LY-CoV1404)	Phase II	Lilly	• COVID-19	
NBL-012	Phase I	NovaRock Biotherapeutics	• dermatology • gastrointestinal disease • immunology	Trianni License
NBL-015	IND approved	NovaRock Biotherapeutics	• oncology	
IVX-01	Clinical field study	Invetx	• animal health	AbCellera Discovery Partnership

COPYRIGHT © ABCELLERA

$5.5M revenue reflects robust discovery partnership activity.



COPYRIGHT © ABCELLERA

Operating expenses continue to reflect strengthening of the platform.

Operating Expenses USD

RESEARCH & DEVELOPMENT



SALES & MARKETING



GENERAL & ADMIN



COPYRIGHT © ABCELLERA

Net loss of $21.4M: Equivalent to ($0.08) per share (basic & diluted).

Earnings / Loss USD

NET EARNINGS (LOSS)



EARNINGS (LOSS) PER SHARE: BASIC & DILUTED



COPYRIGHT © ABCELLERA

Total short-term liquidity nearly $800 million.



Additionally, $44M AR + accrued AR balance at quarter end

1. excluding marketable securities

COPYRIGHT © ABCELLERA

THANK YOU



COPYRIGHT © ABCELLERA